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Oxidative stress and inflammation play a key role in the age-related decline in the respiratory function. 
Adipokine in relation to the metabolic and inflammatory systems is attracting growing interest in 
the field of respiratory dysfunction. The present clinical and experimental studies investigated the 
role of the disulfide bond-forming oxidoreductase A-like protein (DsbA-L) gene, which has antioxidant 
and adiponectin multimeric (i.e. activation) properties, on the respiratory function of the elderly. We 
performed a retrospective longitudinal genotype-phenotype relationship analysis of 318 Japanese 
relatively elderly participants (mean age ± standard deviation: 67.0 ± 5.8 years) during a health 
screening program and an in vitro DsbA-L knock-down evaluation using 16HBE14o-cells, a commonly 
evaluated human airway epithelial cell line. The DsbA-L rs1917760 polymorphism was associated 
with a reduction in the ratio of forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) 
and %FEV1 and with the elevation of the prevalence of FEV1/FVC < 70%. We also confirmed that the 
polymorphism was associated with a decreased respiratory function in relation to a decrease in the ratio 
of high-molecular-weight adiponectin/total adiponectin (as a marker of adiponectin multimerization) 
and an increase in the oxidized human serum albumin (as an oxidative stress marker). Furthermore, we 
clarified that DsbA-L knock-down induced oxidative stress and up-regulated the mucus production in 
human airway epithelial cells. These findings suggest that the DsbA-L gene may play a role in protecting 
the respiratory function of the elderly, possibly via increased systemic adiponectin functions secreted 
from adipocytes or through systemic and/or local pulmonary antioxidant properties.
Airway inflammation and an impaired lung function are common in elderly populations, leading to decreased 
quality of life and increase in morbidity and mortality1–3. Although exposures to cigarette smoke and other envi-
ronmental pollutants (e.g. biomass fuel exposure and air pollution) are major risk factors for the development and 
progression of respiratory dysfunction4,5, previous evidence has shown that age-related changes in the respiratory 
functions are also key factors for respiratory dysfunction1–3. Aging causes the loss of lung elasticity, decreased 
respiratory muscles, and a decreased surface area for alveolar gas exchange, leading to an impaired respiratory 
function1–3. Furthermore, local and/or systemic oxidative stress as well as inflammation play substantial roles in 
the age-related decline in the respiratory function1,2. However, these changes in respiratory pathological features 
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with aging are affected by many other factors, including not only environmental toxins but also genetic predispo-
sition, metabolic status and oxidative stress, and are thus considered to be complex and interactive1–3.
Adiponectin (APN) is an adipose tissue-derived adipocytokine that is abundant in plasma and has 
anti-inflammatory, anti-diabetic and anti-atherogenic properties6–8. Previous clinical trials have indicated that the 
APN level is closely related to the respiratory function parameters9. APN knock-out mice were reported to show 
abnormal alveolarization and increases in both proteolytic and tumor necrosis factor-alpha (TNF-α) activity, 
which resulted in an emphysematous phenotype with an inflammatory condition10. APN decreases the produc-
tion and activity of inflammatory cytokines, including TNF-α and interleukin-6, and increases the production of 
anti-inflammatory cytokines in epithelial cells, monocytes and macrophages9.
Plasma APN exists in three major oligomeric complexes: trimer and hexamer forms and a 
high-molecular-weight (HMW) oligomer that is the major relevant form for improving insulin sensitivity, 
anti-inflammatory and antidiabetic activities. Notably, low levels of the HMW oligomer are an independent 
risk factor for several metabolic diseases11,12. Disulfide bond-forming oxidoreductase A-Like protein (DsbA-L) 
is highly expressed in the endoplasmic reticulum (ER) and mitochondria and was renamed from glutathione 
S-transferase (GST) kappa 113,14. DsbA-L is involved in cell detoxification of xenobiotics, endogenous toxic 
metabolites and free radicals, including toxic metabolites contained in cigarette smoke13. DsbA-L is also reported 
to be an important regulator of APN multimerization in 3T3-L1 cells14 and humans in vivo15. Therefore, the 
DsbA-L gene may affect the decline in the respiratory function, but the details remain unclear.
A common polymorphism in the human DsbA-L gene at -1308 bp (rs1917760) has been identified and can 
influence the DsbA-L expression and activity16. The allele frequency of the rs1917760 polymorphism is reported 
to be approximately 20% in Asians16. Gao et al. previously showed that the DsbA-L rs1917760 polymorphism was 
associated with increased insulin secretion and fat deposition in a cross-sectional study17. Our recent clinical 
investigation revealed that the DsbA-L rs1917760 polymorphism is associated with an increased body mass index 
(BMI) in relation to decreasing the ratio of HMW/total APN15.
In the present study, we performed a clinical pharmacogenomics analysis and an in vitro evaluation to inves-
tigate the role of the DsbA-L gene in the respiratory dysfunction of the elderly. The present findings of this study 
provide insight into potentially novel preventive or therapeutic targets for the age-related decline in the res-
piratory function, which leads to a decreased quality of life and increase in morbidity and mortality in elderly 
individuals1–3.
Results
Association between the DsbA-L genotype and the respiratory function. The study subjects 
included in this study were relatively elderly individuals (mean age ± standard deviation: 67.0 ± 5.8). The demo-
graphic characteristics at baseline of the subjects are shown in Table 1. The genotype frequencies of the DsbA-L 
rs1917760 G/G, G/T and T/T were 56.1%, 37.8% and 6.1%, respectively. The carriers of the DsbA-L T/T geno-
type had lower values of forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) and %FEV1, 
a higher prevalence of FEV1/FVC < 70% and a greater proportion of overweight than those with the G/G or 
G/T genotype at baseline (Table 1). The longitudinal differences in the values of FEV1/FVC and %FEV1 and the 
prevalence of FEV1/FVC < 70% among the DsbA-L genotypes are shown in Fig. 1. FEV1/FVC and %FEV1 values 
differed among the DsbA-L genotypes through the observation period (Fig. 1). The influence of the DsbA-L geno-
type on the respiratory function was also analyzed using multiple regression models adjusted by age, gender, BMI 
and smoking status based on the generalized estimating equations approach (Table 2). The longitudinal values of 
FEV1/FVC and %FEV1 and the prevalence of FEV1/FVC < 70% were found to be significantly higher in the car-
riers of the DsbA-L T/T and/or G/T genotypes than in those with the G/G genotype independently of age, gender, 
BMI and smoking status (Table 2). Since the DsbA-L rs1917760 polymorphism was significantly associated with 
an overweight status15, we performed stratified multivariable analyses by the presence of an overweight status 
(Supplementary Table 2). As a result, the effects of DsbA-L rs1917760 polymorphism on the reduction in the 
respiratory function were found to be more pronounced in overweight subjects than in normal-weight subjects 
(Supplementary Table 2).
Association between the DsbA-L genotype, APN levels and the respiratory function. The mean 
values ± standard deviation of total and HMW APN and the ratio of HMW/total APN (i.e. index of APN mul-
timerization) were 141.0 ± 89.9 ng/mL, 92.4 ± 67.3 ng/mL and 62.6% ± 20.3%, respectively. The value of %FEV1 
was positively correlated with the values of total and HMW APN and the ratio of HMW/total APN (r = 0.187, 
P = 0.001; r = 0.230, P < 0.001; r = 0.210, P = 0.002, respectively) (Fig. 2). In contrast, the value of FEV1/FVC 
was not correlated with the values of total or HMW APN or the ratio of HMW/total APN (r = 0.081, P = 0.156; 
r = 0.073, P = 0.202; r = −0.032, P = 0.577, respectively). Our recent study showed that the ratio of HMW/total 
APN in carriers of the DsbA-L T/T genotype was lower than in those with the G/G or G/T genotype among 
almost similar subjects15. Furthermore, the ratio of HMW/total APN was significantly lower in overweight sub-
jects with the T/T genotype than in normal-weight subjects with the G/G genotype15. We assessed the effect of 
the DsbA-L T allele on APN multimerization in the present study but failed to detect any significant association 
between the DsbA-L T allele and the ratio of HMW/total APN (Table 3).
Association between the DsbA-L genotype, oxidative stress and the respiratory function. The 
mean values ± standard deviation of oxidized human serum albumin (HSA) (as a systemic oxidative stress 
marker) was 44.9% ± 3.6%. The oxidized HSA was not correlated with the value of %FEV1 (r = −0.013, 
P = 0.817) or FEV1/FVC (r = −0.013, P = 0.821). We previously reported that the oxidized HSA tended to be 
higher in carriers of the DsbA-L G/T or T/T genotypes than in those with the G/G genotype among similar 
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subject15. In the present study, a multivariable analysis showed that oxidized HSA levels were significantly higher 
in the carriers of the DsbA-L T allele than in those with the G/G genotype, independent of the BMI (Table 3).
Possible influence of the DsbA-L genotype on the respiratory function, APN multimerization 
and oxidative stress: a pathway analysis. To verify the observed associations of the DsbA-L T/T geno-
type or T allele with the respiratory function, APN multimerization and oxidative stress, we performed a pathway 
analysis using structural equation modeling incorporating other potential risk factors for respiratory dysfunction 
DsbA-L genotype
G/G (n = 178) G/T (n = 120) T/T (n = 20) P
Female (%) 68 (38.2) 51 (42.5) 7 (35.0) 0.689
Age (years) 67.3 ± 5.9 66.4 ± 5.6 67.3 ± 6.0 0.473
BMI (kg/m2) 22.7 ± 2.9 22.6 ± 2.5 23.9 ± 2.2 0.143
FEV1 / FVC (%) 77.5 ± 5.7 75.3 ± 7.3 72.9 ± 7.5 0.001
%FEV1 (%) 99.4 ± 13.4 97.3 ± 16.1 90.2 ± 17.9 0.025
%FVC (%) 108.1 ± 13.6 109.6 ± 14.7 104.5 ± 14.7 0.286
Fasting blood glucose (mg/dL) 100.3 ± 19.7 102.4 ± 19.6 103.8 ± 7.9 0.570
Systolic BP (mmHg) 124.1 ± 18.1 122.7 ± 17.8 121.1 ± 12.9 0.580
Diastolic BP (mmHg) 72.6 ± 10.5 71.4 ± 11.8 73.0 ± 11.4 0.623
LDL-C (mg/dL) 124.8 ± 27.8 123.5 ± 28.0 115.9 ± 25.3 0.390
HDL-C (mg/dL) 69.8 ± 16.6 69.6 ± 16.0 70.9 ± 23.9 0.956
TG (mg/dL) 101.0 ± 53.2 102.9 ± 46.4 98.1 ± 45.2 0.907
FEV1/FVC < 70% (%) 10 (5.6) 13 (10.8) 4 (20.0) 0.046
Overweight (%) 87 (48.9) 54 (45.0) 15 (75.0) 0.046
Diabetes (%) 20 (11.2) 13 (10.8) 2 (10.0) 0.983
Hypertension (%) 75 (42.1) 47 (39.2) 9 (45.0) 0.824
Dyslipidemia (%) 80 (44.9) 55 (45.8) 7 (35.0) 0.661
Ever-smoking status (%) 69 (38.8) 63 (52.5) 10 (50.0) 0.135
Alcohol intake (g/day) 7.7 ± 11.7 7.9 ± 12.8 5.1 ± 8.0 0.619
Table 1. Clinical characteristics stratified by the DsbA-L genotype at baseline. The data are the means ± 
standard deviation, medians (range) or proportions for categorical variables. DsbA-L, disulfide bond-forming 
oxidoreductase A-like protein; BMI, body mass index; FEV1: percent predicted forced expiratory volume in 
1 second; FVC, percent predicted forced vital capacity; BP, blood pressure; LDL-C, low-density lipoprotein 
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Figure 1. Longitudinal differences of the mean values of FEV1/FVC and %FEV1 and prevalence of FEV1/
FVC < 70% between the DsbA-L genotypes. The mean values of FEV1/FVC and %FEV1 and the prevalence 
of FEV1/FVC < 70% are shown as dashed-dotted, dotted, and solid lines for the subjects with the DsbA-L 
G/G, G/T and T/T genotypes, respectively. The bars represent the standard errors or 95% confidence interval. 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; DsbA-L, disulfide bond-forming 
oxidoreductase A-Like protein.
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(e.g. ever-smoking status) (Fig. 3). The fitness statistics goodness of fit index (GFI), adjusted GFI (AGFI), and 
root mean square error of approximation (RMSEA) were 0.987, 0.968 and 0.006, respectively, indicating a good 
fit for the structural equation model. Moreover, all 1000 bootstrap runs exhibited successful minimization and 
were included in the bootstrap analysis. The result of the bootstrap evaluation for this structural equation model 
showed that the mean values, SEs and 95% CIs for all covariates obtained using the bootstrap analysis were gener-
ally comparable to the estimates obtained using the structural equation modeling (Supplementary Table S1). The 
DsbA-L T/T genotype or T allele appears to influence the decreased respiratory function (i.e. reduction in FEV1/
FVC and %FEV1 and increase in the risk of FEV1/FVC < 70%) (Fig. 3). Furthermore, the DsbA-L T/T genotype 
or T allele was also associated with a reduction in the ratio of the HMW/total APN and elevation in the oxidized 
HSA level (Fig. 3). In contrast, an overweight status was independently associated with a reduction in the ratio of 
the HMW/total APN and elevation in the oxidized HSA level (Fig. 3). Moreover, an ever-smoking status was also 
independently associated with a decreased respiratory function (Fig. 3).
DsbA-L 
genotype
FEV1/FVC (%) %FEV1 (%) FEV1/FVC < 70%
B* SE P B* SE P OR* 95% CI P
G/G 0 0 1
G/T −2.393 0.696 <0.001† −2.073 1.724 0.229 2.608 1.240–5.484 0.011†
T/T −3.492 1.554 0.025 −9.223 3.697 0.013† 3.715 1.070–12.896 0.039
G/G 0 0 1
G/T or 
T/T −2.552 0.661 <0.001
† −3.105 1.645 0.059 2.767 1.355–5.650 0.005†
Table 2. Longitudinal associations of the DsbA-L genotype with the values of FEV1/FVC and %FEV1 and the 
prevalence of FEV1/FVC < 70% in the multivariable regression models based on the generalized estimating 
equations approach. *Adjusted by age, gender, BMI, smoking status. †Statistical significance remained following 
the use of Bonferroni’s correction. DsbA-L, disulfide bond-forming oxidoreductase A-like protein; BMI, body 
mass index; %FEV1, percent predicted forced expiratory volume in 1 second; OR, odds ratio; CI, confidence 
interval; SE, standard error.
Figure 2. The correlations of %FEV1 with the total, HMW APN and the ratio of HMW/total APN. Correlation 
coefficients (r) and P values were calculated by Pearson’s correlation test. FEV1, forced expiratory volume in 
1 second; HMW, high-molecular-weight; APN, adiponectin.
DsbA-L 
genotype
HMW/total APN (%) Oxidized HSA (%)
B* SE P B* SE P
G/G 0 0
G/T or 
T/T −0.360 2.276 0.874 1.106 0.395 0.005
Table 3. Associations of the DsbA-L T allele with the HMW/total APN (%) and the oxidized HSA (%) in 
the multiple regression models. *Adjusted by age, gender, BMI and smoking status. DsbA-L, disulfide bond-
forming oxidoreductase A-like protein; HMW, high molecular weight; APN, adiponectin; HSA, human serum 
albumin; BMI, body mass index; B, partial regression coefficient; SE, standard error.
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induction of oxidative stress due to DsbA-L knock-down in human airway epithelial 
cells. DsbA-L is expressed in mitochondria of systemic tissues, including lung tissue18. Given that DsbA-L 
polymorphism affects the decline in the respiratory function according to the results of our human in vivo studies 
(Figs. 1 and 3), there was a possibility that the DsbA-L might also exert a protective role in lung tissue. To explore 
the potential protective mechanisms of DsbA-L against respiratory dysfunction, we first analyzed the oxidative 
stress under the conditions of DsbA-L knock-down and/or treatment with H2O2 (300 μM) in human airway epi-
thelial cells (Fig. 4). DsbA-L knock-down significantly decreased the DsbA-L expression (Fig. 4A). Heme oxygen-
ase (HO)-1, an enzyme that catalyzes the degradation of heme, was increased under both DsbA-L knock-down 
and H2O2 treatment conditions at both mRNA and protein levels (Fig. 4B,C). In addition, the mRNA level of HO-
1 increased additively under conditions of both DsbA-L knock-down and H2O2 treatment (Fig. 4B). Furthermore, 
the elevation of ROS due to DsbA-L knock-down and H2O2 treatment was also detected with DCFDA (Fig. 4D,E). 
Consistently, the reduction of H2O2-induced ROS due to DsbA-L overexpression was detected with DCFDA 
(Fig. 4F,G). However, treatment with H2O2 decreased the DsbA-L mRNA and protein expression, and the DsbA-L 
mRNA-lowering effect by H2O2 became more pronounced with time (Fig. 4H,I).
Up-regulation of mucus production due to DsbA-L knock-down in human airway epithelial 
cells. In order to assess whether or not the DsbA-L gene has a protective role in the accumulation of mucus 
in airway epithelial cells, we analyzed the effect of DsbA-L knock-down on the expression of MUC5AC as a 
mucus gene marker (Fig. 5). In addition, we investigated whether or not c-jun N-terminal kinase (JNK) acts as a 
regulator for DsbA-L knock-down-induced MUC5AC up-regulation. Both DsbA-L knock-down and treatment 
with H2O2 (300 μM) increased the level of MUC5AC mRNA, and the combination of DsbA-L knock down and 
H2O2 treatment additively increased the level of MUC5AC mRNA (Fig. 5A). Furthermore, DsbA-L knock-down 
increased the level of MUC5AC protein and p-JNK/Actin (Fig. 5B–D), and elevation of the level of MUC5AC 
mRNA due to DsbA-L knock-down was attenuated by treatment with SP600125, which is a potent, selective and 
reversible inhibitor of JNK (Fig. 5E).
Discussion
This is the first study to show the influence of the DsbA-L gene on the respiratory function by both clinical and 
experimental procedures. In the present human in vivo study conducted in the Japanese elderly population, the 
DsbA-L rs1917760 polymorphism was involved in the reduction in the respiratory function in conjugation with 
a decrease in the ratio of HMW/total APN and an increase in the oxidized HSA level. The present experimental 
study determined that DsbA-L knock-down induced oxidative stress and up-regulated the mucus production 
in human airway epithelial cells. These findings suggest that the DsbA-L gene may have a role in protecting the 
respiratory function of the elderly, possibly through increased systemic functions of APN secreted from adipo-
cytes or through systemic and/or pulmonary antioxidant properties (Fig. 6). The findings of this study implied 
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Figure 3. The structural equation modeling diagram of the DsbA-L genotype and respiratory function. Lines 
with numbers indicate significant paths with standardized β coefficients (P < 0.05). FEV1, forced expiratory 
volume in 1 second; DsbA-L, disulfide bond-forming oxidoreductase A-Like protein; HMW, high-molecular-
weight; BMI, body mass index.
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Figure 4. DsbA-L knock-down induces oxidative stress in human airway epithelial cells. (A,B) 
16HBE14o- cells were transfected with control or DsbA-L-specific siRNA (50 nM) for 48 hr. After 
preincubation, cells were incubated with H2O2 (300 μM) for 6 hr and then quantitative real-time RT-PCR 
was performed using isolated RNA to determine the level of indicated genes. 18srRNA was used as internal 
control. (C) Immunoblotting with HO-1 antibody was performed with the lysates of siRNA-treated 
(50 nM) and/or H2O2-incubated (300 μM, 6 hr) 16HBE14o- cells. The band intensity was quantified by 
Multi Gauge software. (D,E) DCFDA staining was performed and analyzed with fluorescence microscopy 
in siRNA-treated (50 nM) and/or H2O2-incubated (300 μM, 1 hr) 16HBE14o- cells. (F,G) DCFDA staining 
was performed and analyzed with fluorescence microscopy in two lots of DsbA-L-transfected under H2O2-
incubated (300 μM, 1 hr) primary NHBE cells. (H) Immunoblotting with DsbA-L antibody was performed 
with the lysates of siRNA-treated (50 nM) and/or H2O2-incubated (300 μM, 6 hr) 16HBE14o- cells. The 
band intensity was quantified by Multi Gauge software. (I) 16HBE14o- cells were treated with H2O2 
(200 μM) for 12, 24 and 36 hr and then quantitative real-time RT-PCR was performed using isolated RNA 
to determine the level of DsbA-L gene. 18srRNA was used as internal control. Full unedited gel was shown 
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inducer of DsbA-L14) as a potential preventive or therapeutic approach for combatting the age-related decline in 
the respiratory function.
Although the role of APN in lung tissues is not entirely clear, the association of APN levels with the decline 
in the respiratory function has been highlighted9,19–21. APN, especially HMW APN, has anti-inflammatory and 
protective properties for endothelial functions, which are mainly regulated by suppressing TNF-α produc-
tion, acting on macrophages to promote the removal of early apoptotic cells and inducing the production of 
anti-inflammatory cytokines9. In humans, the mRNA level of DsbA-L in adipocytes was shown to be inversely 
correlated with the BMI14, and the DsbA-L rs1917760 polymorphism was associated with increased insulin secre-
tion and fat deposition17. The findings of our previous study indicated that the influence of the DsbA-L rs1917760 
polymorphism on APN multimerization was more pronounced in overweight subjects than in normal-weight 
subjects15. We therefore speculated that the effect of the DsbA-L T/T genotype on the respiratory function might 
be associated with differences in subjects’ weight status in relation to low APN multimerization.
The cGAS-cGAMP-STING pathway was recently found as a cytosolic DNA sensor of pathogen-derived 
DNA to mediate the innate immune response22. Obesity-induced mtDNA was reported to be associated with 
inflammatory responses due to the activation of the cGAS-cGAMP-STING pathway23. Furthermore, the 
DsbA-L gene was shown to suppress obesity-induced inflammation and insulin resistance by inactivating the 
cGAS-cGAMP-STING pathway23. In the present study, the multivariable analyses showed that the DsbA-L 
rs1917760 polymorphism was associated with a reduction in the respiratory function, even after adjusting for the 
BMI (Table 2), and this association was more pronounced in overweight subjects than in normal-weight subjects 
(Supplementary Table 2). These results suggest that the protective role of DsbA-L against the reduction in the 
respiratory function would be more significant in overweight subjects than in normal-weight subjects. Therefore, 
weight reduction in overweight patients with the DsbA-L T/T genotype carriers may be a simple and effective 
preventive strategy against the age-related reduction in the respiratory function, although further interventional 
studies will be needed.
Nakanishi et al. reported that APN knock-out mice showed an advanced respiratory dysfunction phenotype 
and extrapulmonary effects (e.g. fat atrophy, body weight loss, systemic inflammation and osteoporosis), and 
APN injection was able to suppress the development of respiratory dysfunction10. Another study of rats showed 
that the decline in the respiratory function was ameliorated by the administration of APN through the inhibition 
of ER stress-induced airway epithelial apoptosis24. In our present human study, the levels of total and HMW APN 
and the ratio of HMW/total APN correlated positively with the value of %FEV1 (Fig. 2), suggesting that APN 
might exert a protective role against the respiratory dysfunction. In contrast, plasma HMW APN may also reflect 
the inflammatory status9 or weight status25, rather than the respiratory function, in patients with advanced res-
piratory dysfunction. Therefore, further longitudinal clinical investigations evaluating the influence of APN mul-
timerization on the development and progression of respiratory dysfunctions, while also paying careful attention 
to the weight status, in both healthy subjects and patients with various disease states of respiratory dysfunction 
are needed.
Substantial evidence suggests that increased oxidative stress is a potential pathogenetic mechanism underly-
ing the age-related decline in the respiratory function, and elderly individuals with respiratory dysfunction are 
considered to be in a state of oxidative stress1,2. DsbA-L is also known as GSTK113,14 and not only plays a role 
in APN multimerization but also has activities against a number of substrates associated with oxidative stress 
(e.g. l-chloro-2,4-dinitrobenzene, ethacrynic acid, cumene hydroperoxide and t-butyl hydroperoxide)13. A pre-
vious study showed that the knock-down of the DsbA-L gene in Caenorhabditis elegans resulted in a significant 
decrease in the respiration rate and a change in the fatty acid metabolism in mitochondria26. The present human 
in vivo study also showed that the DsbA-L T allele was associated with increased oxidized HSA levels (Table 3). 
In addition, we showed that the DsbA-L gene knock-down directly induced oxidative stress in human airway epi-
thelial cells (Fig. 4). Therefore, the DsbA-L gene may play an important role in protection against oxidative stress 
and inflammation, possibly by affecting the cellular properties of detoxification of xenobiotics, endogenous toxic 
metabolites and/or free radicals in airway epithelial cells.
Airway mucus hypersecretion is a frequent symptom associated with decline in the respiratory function27. 
Inflammatory reactions, oxidative stress and viral or bacterial infection often cause mucus production, which 
is closely related to poor mucociliary clearance, airway occlusion, reduced peak expiratory flow and respiratory 
muscle weakness28. The ROS-activated JNK signaling pathway was reported to be a major mechanism against 
increased mucus production by cigarette smoking29. In this study, we showed that the knock-down of the DsbA-L 
gene up-regulated mucus production and activated the JNK signaling pathway in human airway epithelial cells 
(Fig. 5). Consistently, Chen et al. reported that the deficiency of DsbA-L is associated with impairment of the 
maximum respiratory capacity, elevated cellular oxidative stress and increased JNK activity30. Thus, the antiox-
idant effect of DsbA-L may act protectively against the decline in the respiratory function, partially through the 
deactivated JNK signaling pathway in lung tissue.
Several limitations associated with the present study should be noted. First, the human study is a retrospec-
tive design and was performed in a relatively small number of subjects. In particular, there were few subjects with 
the DsbA-L T/T genotype (n = 20), so further investigations with a larger number of subjects are needed. Second, 
bronchodilators were not used before lung function tests were conducted, so the respiratory function should be 
evaluated more accurately using bronchodilators. Third, the present human in vivo study showed the systemic role 
in Supplementary Fig. S1. DsbA-L, disulfide bond-forming oxidoreductase A-Like protein; DCFDA, 
2′,7′-dichlorodihydro-fluorescein diacetate acetyl ester. Data are means ± standard error; n = 3 / group. P 
values were assessed by Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.001).
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of DsbA-L in the respiratory function of the elderly, and the present in vitro study showed the local role of DsbA-L 
in lung tissue. However, we were unable to examine whether or not the DsbA-L rs1917760 polymorphism affects 
the lung expression of DsbA-L in this study. In addition, we were unable to assess whether or not individuals with 
the DsbA-L rs1917760 TT genotype also had an increased sputum production or increased frequency of bronchitis. 
Therefore, whether or not a relationship truly exists between the results of the human in vivo study and the in vitro 
study is unclear. Further investigations are needed to determine whether or not the results of the human in vivo study 
are linked to those in the in vitro study. Finally, although our in vitro study revealed the connection between loss of 
DsbA-L and up-regulation of MUC5AC in airway epithelial cell line 16HBE14o- cells both at mRNA and protein 
levels (Fig. 5A,B). However, to make the finding more confident, further analysis such as western blotting or ELISA 
rather than dot-blot-based method to detect MUC5AC protein may be required. We have extensively performed 
western blotting and ELISA, but have never been able to detect MUC5AC protein in 16HBE14o- cells unfortunately 
(data not shown). Future experiments using primary airway epithelial cells may help to show physiological relevance 
of MUC5AC up-regulation under the condition with DsbA-L down-regulation.
conclusion
The current human in vivo study revealed the potential association of the DsbA-L gene with the respiratory func-
tion from the perspective of systemic APN multimerization and the oxidative stress state in a relatively healthy 
elderly population (Fig. 6). In addition, our in vitro investigations indicated that the DsbA-L gene in local lung 
tissue plays a protective role against respiratory dysfunction through its antioxidant activity (Fig. 6). The results 
Figure 5. DsbA-L knock-down up-regulates mucus production through JNK signaling activation in human 
airway epithelial cells. (A) 16HBE14o- cells were transfected with control or DsbA-L-specific siRNA (50 nM) for 
48 hr. After preincubation, cells were incubated with H2O2 (300 μM) for 6 hr and then quantitative real-time RT-
PCR was performed using isolated RNA to determine the level of MUC5AC gene. (B) Condition medium from 
16HBE14o- cells transfected with or without DsbA-L-specific siRNA (50 nM) for 48 hr were subjected to Slot-
blot analysis to detected MUC5AC protein. The band intensity was quantified by Multi Gauge software. (C,D) 
Immunoblotting with indicated antibodies were performed with the lysates of siRNA-treated (50 nM, 48 hr) 
16HBE14o- cells. The band intensity was quantified by Multi Gauge software. (E) MUC5AC gene expression of 
SP600125 (20 μM, 6 hr)-treated 16HBE14o- cells transfected with or without DsbA-L-specific siRNA (50 nM, 
48 hr) were measured by quantitative real-time RT-PCR. 18srRNA was used as internal control. Full unedited 
gels were shown in Supplementary Figs. S2–S5. DsbA-L, disulfide bond-forming oxidoreductase A-Like protein; 
JNK, c-jun N-terminal kinase. Data are means ± standard error; n = 3 / group. P values were assessed by 
Student’s t test (*P < 0.05, **P < 0.01).
9Scientific RepoRtS |         (2020) 10:5973  | https://doi.org/10.1038/s41598-020-62872-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
of this study suggest that the DsbA-L gene may play a role in protecting the respiratory function of the elderly, 
possibly through the increased systemic adiponectin functions secreted from adipocytes or systemic and/or local 
pulmonary antioxidant properties, although further studies are needed to verify the present findings.
Methods
Human studies. Subjects and study protocol. All subjects were Japanese participants in the elderly health 
screening program held by the Japanese Red Cross Kumamoto Health Care Center. A retrospective longitudi-
nal analysis for 5.5 ± 1.1 years of follow-up was conducted among 318 subjects (age [range]: 67.5 ± 6.0 [56–84] 
years, BMI [range]: 22.7 ± 2.8 [15.8–35.2] kg/m2). Based on the subjects’ medical history, those with lung diseases 
other than airway obstruction, such as asthma, tuberculosis and lung cancer, were excluded from this study. The 
study complies with the Declaration of Helsinki and was approved by the ethics committees of the Faculty of Life 
Sciences at Kumamoto University and the Japanese Red Cross Kumamoto Health Care Center. All of the subjects 
provided their written informed consent prior to enrollment in the study. All analyses were performed in accord-
ance with Ethical Guidelines for Epidemiological Research in Japan.
Measurements. The clinical information was recorded at each follow-up visit (i.e. at yearly intervals). The lab-
oratory tests were performed using the standard methods of the Japan Society of Clinical Chemistry. The infor-
mation regarding smoking habits and alcohol intake was obtained via face-to-face interviews with healthcare 
providers. Overweight and normal-weight status were defined as a BMI ≥ 23 kg/m2 and BMI < 23 kg/m2, respec-
tively, based on the BMI cut-off point for identifying at-risk Asian Americans for type 2 diabetes screening31.
Genotyping. Genomic DNA was extracted from whole blood using a DNA purification kit (FlexiGene DNA 
kit; QIAGEN, Hilden, Germany). DsbA-L rs1917760 (-1308G > T) genotype was determined using a real-time 
TaqMan allelic discrimination assay (Applied Biosystems, Waltham, MA, USA) in accordance with the manu-
facturer’s protocol (assay no. C_11980950_10). To ensure the genotyping quality, we included DNA samples as 
internal controls, hidden samples of a known genotype, and negative controls (water).
Figure 6. Proposed mechanisms by which DsbA-L protects the age-related decline in the respiratory function. 
DsbA-L, disulfide bond-forming oxidoreductase A-Like protein; HMW, high-molecular-weight; APN, 
adiponectin.
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Adiponectin measurements. To assess the associations of the DsbA-L genotype or respiratory function with APN 
multimerization, we measured the levels of total and HMW APN in serum at the endpoint of the observation 
period according to the methods that we reported previously15.
Measurement of oxidized HSA. To assess the association of the DsbA-L genotype and respiratory func-
tion with oxidative stress, we measured the redox state of HSA, which was reported to be a sensitive systemic 
oxidative stress marker32,33, in serum at the endpoint of the observation period according to our previously 
reported method15. The values of each of the albumin fractions (for human mercapto-albumin [HMA], human 
non-mercapto-albumin [HNA]1 and HNA2) were estimated by dividing the area of each fraction by the total area 
corresponding to HSA. A mixture of HNA1 and HNA2 was defined as oxidized HSA15.
In vitro experiments. Reagents and antibodies. SP600125 was purchased from Enzo Life Sciences, Inc. 
(Farmingdale, NY, USA). Antibodies against phospho-ERK 1/2 (Thr-202/Tyr204), phospho-p38 MAPK (Thr-
180/Tyr-182), phospho-JNK 1/2 (Thr183/Tyr185) and phospho-EGFR (Tyr1068) were purchased from Cell 
Signaling Technology, Inc. (Beverly, MA, USA). Monoclonal antibody against β-actin was purchased from 
Sigma-Aldrich Japan (Tokyo, Japan). Antibody against γ-tubulin was purchased from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA). MUC5AC antibody was purchased from Thermo Fisher Scientific Inc. (Waltham, 
MA, USA). Antibody against HO-1 was purchased from Abcam (UK).
Cell culture. 16HBE14o-cells were generated as reported previously34 and grown in fibronectin/vitrogen/
BSA-coated flask in MEM (Invitrogen, Inc., Carlsbad, CA, USA)35. These cells were maintained in MEM supple-
mented with 10% fetal bovine serum, 2% penicillin/streptomycin. Primary normal human bronchial epithelial 
(NHBE) cells were purchased from LONZA (Basel, Switzerland) and maintained according to the manufac-
turer’s instructions35. All cells were cultured in a humidified incubator at 37 °C and 5% CO2. ON-TARGETplus 
SMARTpool GSTK1 (DsbAL) siRNA (siDsbAL) (GE Healthcare Dharmacon, Inc., Lafayette, CO, USA) and 
control GL2 siRNA36 were transfected into 16HBE14o cells using Lipofectamine RNAiMAX (Thermo Fisher 
Scientific, Inc.). GSTK1 (DsbAL) plasmids in pcDNA3.1 + /C-(K)DYK (#1 and #2 correspond to NM_015917 
and NM_001143679, respectively) were obtained from GenScript, Inc. (Piscataway, NJ, USA). These plasmids 
or pcDNA3.1 empty plasmid were transfected into NHBE cells using the Avalanche Transfection Reagent (EZ 
Biosystems, Maryland, USA), according to the manufacturer’s instructions.
A real-time quantitative reverse transcription (RT)-polymerase chain reaction (PCR) analysis. Quantitative 
RT-PCR was performed by protocols that were previously reported37. After reverse transcription, we performed 
real-time PCR with iQ5 (Bio-Rad) in a mix containing DNA polymerase and SYBR Green (PR820; Takara Bio, 
Inc., Shiga, Japan). The relative quantity of the target gene expression was normalized using human 18srRNA as 
the internal control and expressed as the relative quantity of target gene expression (fold induction). PCR ampli-
fication was performed in triplicate, and the reaction protocol included pre-incubation at 95 °C to activate Ex Taq 
HS for 30 s, amplification of 40 cycles set for 15 s at 95 °C, and annealing for 60 s at 60 °C. The sequences of primers 
used for real-time PCR are shown in Table 4.
Slot and Western blotting analyses. Human bronchial epithelial cells were lysed in lysis buffer and sub-
jected to SDS-PAGE and a Western blot analysis38. Blots were reacted for 2 h with monoclonal antibody diluted 
at 1:1000 and with the respective HRP-conjugated secondary antibodies diluted at 1:2000. After each antibody 
reaction, membranes were washed 3 times with 0.1% TBS-Tween, and blots were visualized with Super Signal 
West Pico chemiluminescence substrate (Thermo Fisher Scientific, Inc.). Images were captured by LAS-4000 
(GE HealthCare Dharmacon, Inc.). The band intensity was quantified using the Multi Gauge software program 
(FUJIFILM, Inc., Tokyo, Japan). For the detection of MUC5AC protein secretion into the medium, slot blotting 
was performed as previously described39.
ROS detection. ROS production was detected using 2′,7′-dichlorodihydro-fluorescein diacetate acetyl ester 
(CM-H2DCFDA) (Invitrogen, Inc.) dye according to the manufacturer’s instructions. Pictures were taken using 
BioRevo BZ-9000 (Keyence, Inc., Tokyo, Japan). Exposure times were kept constant within each trial.
Statistical analyses. Categorical variables were compared using Fisher’s exact test. Student’s t-test or 
a one-way analysis of variance were used to compare the differences in the continuous parametric valuables. 
Nonparametric data were analyzed using the Mann-Whitney U test or Kruskal-Wallis test. The associations of 
the DsbA-L genotype with the prevalence of FEV1/FVC < 70% and the longitudinal differences in the FEV1/
Human 
mRNA Forward primer Reverse primer
18srRNA 5′- CGGCTACCACATCCAAGGAA-3′ 5′- GCTGGAATTACCGCGGCT-3′
MUC5AC 5′-CAGCCACGTCCCCTTCAATA-3′ 5′-ACCGCATTTGGGCATCC-3′
DsbA-L 5′-TCTGGAAAAGATCGCAACGC-3′ 5′- GCCCAAAGGCTCCGTATCTG -3′
HO-1 5′-GGGAATTCTCTTGGCTGGCT -3′ 5′- GCTGCCACATTAGGGTGTCT -3′
Table 4. Primers used for quantitative RT-PCR. RT-PCR, reverse transcription-polymerase chain reaction; 
DsbA-L, disulfide bond-forming oxidoreductase A-Like protein; HO-1, heme oxygenase 1.
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FVC and %FEV1 were examined using logistic regression analyses with calculations of the odds ratios (ORs) and 
95% confidence intervals (95% CIs) and using multiple linear regression analyses with calculations of the partial 
regression coefficients (Bs) and standard errors (SEs), based on the generalized estimating equations approach40. 
Multiple linear regression analyses were performed to compare the differences in the total, HMW APN, ratio 
of HMW/total APN and oxidized HSA among the DsbA-L genotypes, and the effects were adjusted for poten-
tially confounding factors. Structural equation modeling was used to perform the pathway analysis assessing 
the effects of the DsbA-L genotype on the respiratory function in association with APN multimerization and 
oxidative stress. The goodness-of-fit on the structural equation modeling was evaluated based on the following 
criteria: GFI > 0.90, AGFI > 0.90, and RMSEA < 0.10. In order to examine the accuracy of the parameters of the 
structural equation model, bootstrap analysis was performed using 1000 replicated datasets generated by random 
sampling with replacement.
A value of P < 0.05 was considered to be statistically significant. Multiple comparisons were performed by 
Bonferroni’s correction, and P values < 0.05/number of comparisons made were considered to be statistically 
significant. The structural equation modeling process and the other statistical analyses were performed using 
the SPSS Amos software program (version 23.0; IBM Japan, Inc., Tokyo, Japan) and the SPSS software package 
(version 23.0; IBM Japan, Inc.), respectively.
Data availability
The datasets generated and/or analyzed during the current study are not publicly available due to individual 
privacy but are available from the corresponding authors on reasonable request.
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